
    unexpected toxicity
  
['acute myeloid leukemia']
['cytarabine', 'nivolumab', 'cytarabine', 'nivolumab']

        Inclusion Criteria:

          -  Patients with a diagnosis of acute myeloid leukemia with the confirmed first or second
             complete remission

          -  ≥ 55 years of age

          -  Not candidates for allogeneic stem cell transplantation as decided by the panel of
             hematologists at the transplant center

          -  Patients with a HLA-haploidentical donor who should be able to provide informed
             consent for peripheral blood apheresis

          -  No severe concurrent illness that limits life expectancy to less than 2 years

        Exclusion Criteria:

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Karnofsky index <70%

          -  Acute promyelocytic leukemia

          -  Other tumor requiring treatment at the time of enrollment

          -  Active or prior documented autoimmune disease requiring systemic treatment

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent
      